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ARTICLE OPEN
Early changes in glioblastoma metabolism measured by MR
spectroscopic imaging during combination of anti-angiogenic
cediranib and chemoradiation therapy are associated with
survival
Ovidiu C. Andronesi1, Morteza Esmaeili1,7, Ronald J. H. Borra1,3,8, Kyrre Emblem1,9, Elizabeth R. Gerstner2, Marco C. Pinho1,10,
Scott R. Plotkin2, Andrew S. Chi2,11, April F. Eichler2,12, Jorg Dietrich2, S. Percy Ivy4, Patrick Y. Wen5, Dan G. Duda6, Rakesh Jain6,
Bruce R. Rosen1, Gregory A. Sorensen1,13 and Tracy T. Batchelor2
Precise assessment of treatment response in glioblastoma during combined anti-angiogenic and chemoradiation remains a
challenge. In particular, early detection of treatment response by standard anatomical imaging is confounded by pseudo-response
or pseudo-progression. Metabolic changes may be more speciﬁc for tumor physiology and less confounded by changes in
blood–brain barrier permeability. We hypothesize that metabolic changes probed by magnetic resonance spectroscopic imaging
can stratify patient response early during combination therapy. We performed a prospective longitudinal imaging study in newly
diagnosed glioblastoma patients enrolled in a phase II clinical trial of the pan-vascular endothelial growth factor receptor inhibitor
cediranib in combination with standard fractionated radiation and temozolomide (chemoradiation). Forty patients were imaged
weekly during therapy with an imaging protocol that included magnetic resonance spectroscopic imaging, perfusion magnetic
resonance imaging, and anatomical magnetic resonance imaging. Data were analyzed using receiver operator characteristics, Cox
proportional hazards model, and Kaplan–Meier survival plots. We observed that the ratio of total choline to healthy creatine after
1 month of treatment was signiﬁcantly associated with overall survival, and provided as single parameter: (1) the largest area under
curve (0.859) in receiver operator characteristics, (2) the highest hazard ratio (HR = 85.85, P = 0.006) in Cox proportional hazards
model, (3) the largest separation (P = 0.004) in Kaplan–Meier survival plots. An inverse correlation was observed between total
choline/healthy creatine and cerebral blood ﬂow, but no signiﬁcant relation to tumor volumetrics was identiﬁed. Our results
suggest that in vivo metabolic biomarkers obtained by magnetic resonance spectroscopic imaging may be an early indicator of
response to anti-angiogenic therapy combined with standard chemoradiation in newly diagnosed glioblastoma.
npj Precision Oncology  (2017) 1:20 ; doi:10.1038/s41698-017-0020-3
INTRODUCTION
Altered metabolism is a hallmark of cancer, which has been
recognized as an important mechanism and biomarker for
cancer.1, 2 In the particular case of glioblastoma (GBM) there is
signiﬁcant alteration in the metabolic proﬁle compared to the
healthy brain tissue that can be detected in patients using in vivo
magnetic resonance spectroscopy.3–5 While initial diagnosis is
always conﬁrmed by histopathology and molecular analysis of
surgical specimens,6, 7 repeated biopsies are not feasible for
treatment monitoring in brain tumor patients. On the other hand,
imaging can be repeated safely to monitor treatment response, it
has the potential to provide objective and precise assessment of
response rates in clinical trials, and it could be used to accelerate
translation of new therapies. However, conventional anatomical
imaging may be ambiguous, often showing signs of pseudo-
response (PdR) in the case of angiogenic (AA) therapy or pseudo-
progression (PdP) for chemoradiation, respectively.8–11 Because of
its reliance on biochemistry, magnetic resonance spectroscopic
imaging (MRSI) has the potential to address the true/PdR and the
true/PdP conundrum. This has motivated us to investigate its
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value in monitoring newly diagnosed GBM patients treated
with adjuvant AA therapy in combination with standard
chemoradiation.
Current standard of care for patients with GBM, the most
common and aggressive primary brain tumor in adults, is surgical
resection followed by fractionated, local radiation, and temozolo-
mide.12 Despite aggressive therapy, disease progression is
universal and median patient survival is 15 months.13 Thus, there
is an urgent need to identify therapies that increase GBM patient
survival. A fundamental pathophysiological hallmark in GBM is the
abnormal tumor vasculature with increased vessel caliber,
tortuosity, and permeability14, 15 that creates an abnormal tumor
microenvironment characterized by hypoxia, acidosis, and ele-
vated ﬂuid pressure which fuels tumor progression and treatment
resistance.16 These abnormalities are associated with the
increased expression of vascular endothelial growth factor (VEGF)
and other pro-angiogenic cytokines that stimulate endothelial cell
proliferation, migration, and survival.17 Compounds that inhibit
blood vessel formation, reduce vessel permeability, and alleviate
edema have been developed for treating GBM.18 Although many
of these compounds have promising efﬁcacy in preclinical studies,
clinical trials on humans have been less successful showing that
only a subset of GBM patients may beneﬁt from AA therapy. Given
the adverse effect proﬁle and high cost of AA drugs it is important
to predict which patients may beneﬁt and which should avoid AA
therapy. Ideally, a method that objectively predicts early the
treatment success or failure would have the greatest impact on
patient management. The Response Assessment in Neuro-
Oncology (RANO) criteria have been speciﬁcally designed19, 20 to
better assess radiological response in glioma patients treated with
AA drugs. However, RANO does not ﬁt well with the paradigm of
early prediction since it requires late conﬁrmatory scans to rule
out PdR/PdP.
Herein, we report results from a prospective longitudinal
imaging study of newly diagnosed GBM patients treated with
the AA drug cediranib (AstraZeneca), an oral pan-VEGF receptor
(VEGFR) tyrosine kinase inhibitor, in combination with standard of
care temozolomide and radiation. We hypothesized that meta-
bolic biomarkers acquired by 1H MRSI may predict patient
outcomes to combination of cediranib with chemoradiation. 1H
MRSI can reliably detect metabolites such as choline-containing
metabolites (total choline, tCho), N-acetyl aspartate (NAA), and
creatine (Cr), which generate the dominant signals in brain
spectra. A previous study in recurrent GBM patients treated with
cediranib monotherapy showed that these metabolites correlated
with patient outcomes.21 Other studies have found that MRSI is
valuable in monitoring temozolomide treatment in glioma
patients22 and radiotherapy in GBM patients.23, 24 However, these
studies were performed with a limited number of observations at
typical clinical follow-up times, which historically have not been
optimized for early detection of treatment response. Our imaging
study was designed with the goal of identifying early signs of
treatment response. In our imaging protocol we employed weekly
scans during the 6 weeks of chemoradiation, which allowed us to
closely examine the dynamics of tumor response with unprece-
dented temporal detail. The goal of our data analysis was to
understand the mechanisms of combination treatment, and
investigate whether synergistic effects exist between AA therapy
and standard chemoradiation.
RESULTS
Across serial scans the radiological response to therapy was
assessed based on changes relative to baseline. In addition to
MRSI metabolic changes, other magnetic resonance imaging (MRI)
biomarkers such as volume of contrast enhanced T1 (ce-T1),
volume of vasogenic edema estimated by FLAIR (Fluid-Attenuated
Inversion Recovery) hyperintensity, and relative cerebral blood
ﬂow (rCBF) were compared for predicting treatment response.
Molecular markers such as MGMT (O6-methylguanine-DNA-
methyltransferase),25 clinical measures such as Karnofsky perfor-
mance score (KPS) and demographics variables (Age) were
assessed in combination with imaging biomarkers.
For MRSI analysis 21 out of 40 patients had data that fulﬁlled the
quality control criteria for longitudinal analysis: (1) consistent
positioning of volume of interest (VOI) at baseline and follow-up
scans, (2) sufﬁcient spectral quality based on signal to noise ratio
(>5), line width (<10 Hz), and (3) absence of major artifacts such as
subcutaneous lipid contamination and poorly suppressed water.
Across the ten time points the number of patients with analyzable
MRSI data varied as follows: 21 at baseline (for both days −5 and
−1), 14 at day +1, 12 at day +8, 9 at day +15, 11 at day +22, 21 at
day +29, 17 at day +36, 14 at day +43, 12 at day +50. In total we
analyzed 162 MRSI data sets, and each MRSI had a VOI that
included between 192 and 400 voxels. Missing MRSI follow-up
scans were not only due to poor data quality, but mostly because
the positioning of the MRSI was not consistent along time points.
Often, data were not acquired at some visits in several patients
due to time constraints, which accounted for 62% of missing data,
or due to patients missing the scan altogether (4%). For the other
MRI modalities (ce-T1, FLAIR, rCBF), the number of patients varied
between 17 and 21 across the ten scans.
In the group of 21 patients the median progression-free survival
(PFS) was 8.8 months (95% conﬁdence interval (CI):
8.2–15.6 months) and median overall survival (OS) was
18.2 months (95% CI: 17.0–27.9 months). Patients were dichot-
omized into two groups based on their median OS: patients with
short OS (<18.2 months), and patients with long OS
(>18.2 months).
In Fig. 1 representative imaging data are shown for a short OS
patient and a long OS patient, respectively. In the case of the short
OS patient (Fig. 1, left) the metabolic maps of tCho/NAA and tCho/
healthy creatine (hCr) show a tumor region with elevated choline
metabolism that is maintained across time points despite
reduction in volumes of ce-T1 and FLAIR, and normalization of
tumor rCBF. In the case of the long OS patient (Fig. 1, right) there
was a signiﬁcant reduction in levels of both tCho/NAA and tCho/
hCr accompanied by normalization (increase) of rCBF. Also, there
was a decrease of the tumor region showing elevated choline, ce-
T1 uptake, and FLAIR hyperintensity.
The median time courses of each imaging biomarker are shown
in Fig. 2 for both groups of patients. Out of the 21 patients
selected for this analysis, 12 patients had short OS and 9 patients
had long OS. The median OS in the short OS group was 405 days,
compared with the median OS in the long OS group, which was
1009 days. Figure 2 shows different behavior of imaging
biomarkers over time: (i) ce-T1 and FLAIR decrease in both
groups, (ii) tCho/hCr is relatively stable in short OS and decreases
in long OS patients, (iii) rCBF increases in long OS and decreases in
short OS patients. However, two general observations can be
made: (1) the changes are larger and faster in long OS patients
compared with short OS, (2) the differences between the two
groups get smaller at the end of time interval. Of note, there are
larger differences between long and short OS patients in the time
courses of metabolic–physiological biomarkers tCho/Cr and rCBF,
compared with those observed by the common structural
biomarkers ce-T1 and FLAIR. The largest differences between
short/long OS time courses are noticed between days 15 and 29.
Importantly, the median ce-T1 time courses of the two groups are
superimposable until day 15, while the other biomarkers diverge
earlier. This is important since AA therapy produces early and
drastic changes in the appearance of ce-T1, yet these early
changes are not speciﬁc enough to differentiate short vs. long OS
patients. This has potentially important implications for clinical
care since ce-T1 is one of the most commonly utilized examina-
tions in brain tumor imaging protocols.
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Since the largest differences were noticed within the time
interval of +[15–29] days we performed further analysis for these
time points, and in particular at day +29 for which we had the
same number of patients as in baseline for all imaging modalities.
Cox proportional hazard model was performed to investigate
the signiﬁcant contribution of MR covariates to predict OS. In
addition to imaging biomarkers, molecular biomarkers (MGMT),
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Fig. 1 Longitudinal imaging in GBM patients treated with cediranib in combination with standard chemoradiation. Metabolic, perfusion, and
anatomical MR images are shown from a patient with short OS (left) and long OS (right). The short OS patient is representative for PdR with
rapid decrease of ce-T1; however, tCho/hCr and tCho/NAA remain elevated. In long OS patient, the decrease of ce-T1 is accompanied by
decrease of tCho/hCr and tCho/NAA. Spectra from a region inside tumor are shown on the upper row. The red rectangle overlaid on ce-T1
images indicates the VOI covered by the MRSI acquisition
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included in the Cox model. Both univariate and multivariate
analysis were performed. Table 1 summarizes all the results,
including regression coefﬁcients (B), the effect sizes given as
hazard ratios (HR = exp(B)), and P-values for each of the covariates
in relation to OS. In the univariate Cox regressions each covariate
was independently assessed and the only statistical signiﬁcant
relation with OS was found for: tCho/hCr (P = 0.006), MGMT status
(P = 0.008), age (P = 0.015), and KPS (P = 0.032). Decrease of tCho/
hCr, positive MGMT methylation, younger age, and higher KPS
were associated with longer OS. Importantly, the largest effect size
was noticed for tCho/hCr where a unit increase was associated
with 86 times increase in HR. The best two imaging biomarkers
tCho/hCr (P = 0.006) and rCBF (CBF-GE, P = 0.108) were combined
in a single index tCho/hCr + rCBF. The combined imaging index
tCho/hCr + rCBF was also analyzed with a univariate Cox model
and was found to have the highest statistical signiﬁcance (P =
0.001). In the multivariate Cox regression we performed two types
of analysis. In the ﬁrst type of multivariate analysis we included
two covariates, comparing the imaging index tCho/hCr + rCBF
against the other signiﬁcant covariates MGMT, age, KPS separately.
In the bivariate analysis tCho/hCr + rCBF maintains the highest HR
and highest statistical signiﬁcance compared with the other
covariates. In the second type of multivariate analysis we included
four covariates, using the combined imaging index tCho/hCr +
rCBF, FLAIR volume, MGMT status, and age. The combined
imaging index tCho/hCr + rCBF was the covariate that was
signiﬁcantly associated with OS and showed a largest effect size.
In addition, surgical resection is known to impact survival in GBM
patients. However, the majority of patients in our cohort had
surgical resections and an analysis of the association between
surgery and survival could not be made.
In addition, we also investigated the potential of baseline values
of MR parameters, molecular markers, clinical score, and demo-
graphics for predicting OS. Results summarized in Supplementary
Table 1 show statistical signiﬁcant association between baseline
values and OS in the case of: rCBF (P = 0.03), tCho/hCr (P = 0.02),
volume of ce-T1 (P = 0.002), volume of FLAIR (P < 0.001), KPS (P =
0.032), and Age (P = 0.015).
Receiver operator characteristic (ROC) analysis was performed
using fractional change at day +29 relative to baseline for ce-T1,
FLAIR, rCBF, tCho/hCr, and combined tCho/hCr + rCBF index.
Fractional changes were based on volumes for ce-T1 and FLAIR,
and mean tumor region of interest (ROI) values for rCBF and tCho/
hCr. Area under the curve (AUC), threshold, sensitivity, and
speciﬁcity were determined for all biomarkers. Numerical results of
ROC analysis are summarized in Table 2 and graphically plotted in
Fig. 3. The highest AUC = 0.864 was obtained for combined tCho/
hCr + rCBF index, followed by tCho/hCr with AUC = 0.859, rCBF
with AUC = 0.736, FLAIR with AUC = 0.609, and ce-T1 with AUC =
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rCBF
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tCho/hCr
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Median OS = 405 days MedianOS = 1009days
Fig. 2 Fractional changes of ce-T1 volume, FLAIR volume, rCBF, and tCho/hCr ratio in GBM patients treated with cediranib in combination with
standard chemoradiation. Median time courses in short and long OS patients are shown, and vertical bars represent standard error of
measurement (s.e.m.)
Table 1. Cox proportional hazard model of imaging, molecular, clinical, and demographic biomarkers
Univariate analysis Multivariate analysis I Multivariate analysis II
Variables B HR P-value B HR P-value B HR P-value
Vol-CE 0.63 1.89 0.499
Vol-FLAIR 0.47 1.60 0.415 0.69 2.01 0.577
CBV-SE −1.77 0.17 0.171
CBV-GE −1.17 0.31 0.133
CBF-SE −1.08 0.34 0.267
CBF-GE (rCBF) −0.98 0.38 0.108
tCho/NAA 1.57 4.83 0.158
tCho/hCre 4.45 85.85 0.006
MGMT −2.21 0.11 0.008 −1.79 0.17 0.049 −1.34 0.26 0.216
Age −0.07 0.93 0.015 −0.05 0.96 0.131 −0.03 0.97 0.365
KPS −3.93 0.02 0.032 0.11 1.11 0.958
tCho/hCr + rCBF 0.39 1.47 0.001 0.59 1.79 0.019
0.72 2.04 0.001 0.65 1.91 0.035
0.76 2.14 0.002
P-values less than 0.05 are shown in bold
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above the line of unity (pure chance), which reﬂects their
diminished value to predict survival and treatment response to
anti-VEGFR therapy. Additional ROC analysis performed for base-
line values (Supplementary Fig. 1) showed that tCho/hCr at
baseline had the highest AUC = 0.836.
Using the thresholds derived from ROC analysis we investigated
how each imaging biomarker predicts patient outcome and
survival. Patients were split in two groups based on the relative
change in the corresponding imaging parameter at day +29 to be
below or above the threshold, and the OS was calculated for each
group (Supplementary Fig. 2A). It can be seen that the OS values
calculated based on tCho/hCr patient stratiﬁcation were the
closest to the true OS values. Using tCho/hCr patient stratiﬁcation
the time courses were calculated for each imaging biomarker
(Supplementary Fig. 2B), showing large separation for rCBF and
tCho/hCr but overlap for ce-T1 and FLAIR, similar to results of
Fig. 2.
The fractional change in tCho/hCr, rCBF, FLAIR volume, and ce-
T1 volume at days +15 and +29 relative to baseline were further
analyzed in relation to PFS and OS duration in Fig. 4. Spearman
correlation analysis showed that fractional change of tCho/hCr
was negatively correlated with OS at both day +15 (P = 0.07, R =
−0.64) and day +29 (P < 0.001, R = −0.77). Fractional change of
rCBF showed positive Spearman correlation at day +15 (P = 0.03, R
= 0.49) and day +29 (P = 0.03, R = 0.46). There was a trend for
negative correlation between fractional changes of tCho/hCr and
rCBF (P = 0.08, R = −0.39). There was no correlation between
fractional changes of tCho/hCr and those of ce-T1 or FLAIR.
Volumes of FLAIR and ce-T1 showed no signiﬁcant correlation with
OS for the same time points. With regard to PFS, only ce-T1
volume at day +29 showed a signiﬁcant negative correlation (P =
0.03, R = −0.47), which is to be expected since PFS is often decided
based on radiological criteria. However, no signiﬁcant correlation
was observed between PFS and OS. Using the ROC-derived
thresholds at day +29, log-rank Kaplan–Meier survival curves were
determined for all imaging biomarkers. Survival curves obtained
by tCho/hCr (P = 0.004) and rCBF (P = 0.02) were signiﬁcantly
different in short OS and long OS patients, while no signiﬁcant
separation was obtained with ce-T1 and FLAIR.
DISCUSSION
Imaging has a unique potential to facilitate clinical translation of
novel therapies in glioma.26 While OS remains the gold standard
in evaluating therapeutic beneﬁt, radiographic endpoints that
correlate with the clinical endpoint are valuable for providing early
prediction of response to therapy. In addition to reducing time
and costs of clinical trials, imaging is less confounded by previous
treatments in comparison with OS (patient crossover), and can
objectively quantify effects of therapy (objective response rate).
Currently, PFS, which is typically determined using anatomical
imaging, represents a surrogate endpoint used to stratify glioma
patients. However historically, anatomical imaging (ce-T1, FLAIR)
in GBM patients has shown limited speciﬁcity for early anti-tumor
treatment effects.8–11 Hence, more speciﬁc modalities are needed
to exploit the full potential of imaging.27 Our study provides
evidence that supports MRSI as a potentially valuable modality. In
particular, we focused on the value of metabolic biomarkers
derived from MRSI to monitor patients and assess treatment
response.
Assessing response to AA therapy is particularly challenging
based on anatomical imaging.8, 19, 20, 28 Indeed, data from our
current study showed no signiﬁcant correlation of ce-T1, FLAIR,
and PFS with OS. Since AA therapy rapidly restores the
permeability of the blood–brain barrier (BBB), reducing contrast
leakage and edema probed by ce-T1 and FLAIR, these imaging
modalities may become decoupled from the evolution of tumor
behind a restored BBB. MRSI, which can probe the tumor
metabolic proﬁle irrespective of BBB status, may provide a
window into such an invisible tumor during early stages of AA
therapy. Such information may be valuable in understanding the
mechanisms of AA therapy, its adjuvant role, and how it interacts
with concomitant standard chemoradiation.
One hypothesis is that AA drugs act synergistically with
standard chemoradiation in GBM patients by promoting
Table 2. ROC analysis of the imaging biomarkers
Biomarker AUC Sensitivity Speciﬁcity Threshold
ce-T1 0.600 0.60 0.60 0.65
FLAIR 0.609 0.50 0.60 0.85
rCBF (CBF-GE) 0.736 0.80 0.75 1.05
tCho/hCr 0.859 0.90 0.82 0.91
tCho/hCr + rCBF 0.864 0.90 0.91 2.06
tCho/hCr + rCBF,  AUC = 0.864
rCBF,                    AUC = 0.736
tCho/hCre,            AUC = 0.859
1 - Specificity1 - Specificity
1,00,80,60,40,20,01,00,80,60,40,20,0
ce-T1,      AUC = 0.600
FLAIR,     AUC = 0.609
rCBF,       AUC = 0.736

























Fig. 3 a Receiver operating characteristic (ROC) curves for tCho/hCr, FLAIR volume, ce-T1 volume and rCBF. b The combined tCho/hCr + rCBF
index provides an improvement over tCho/hCr and rCBF alone. Area under curve (AUC) is indicated for each biomarker
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functional blood perfusion in the tumor, hence a more efﬁcient
delivery of cytotoxic therapy (temozolomide) and oxygen to
enhance the genotoxic effects of radiation and chemotherapy.29–31
Data from our study showing that a decrease of tumor metabolic
activity (tCho/hCr) correlates with increased blood perfusion
(rCBF) in responsive patients support this synergistic mechanism
early during treatment. The vascular normalization and beneﬁt of
AA seems to be transient and limited to the ﬁrst month of
treatment (prior to day +29), resulting in a biphasic response with
distinctive early and late behavior seen in the time courses of
tCho/hCr and rCBF. Our MRSI data show a transient large decrease
in the metabolic activity (tCho/hCr) of tumors between days +15
and +29 in patients that respond to combination of AA and
chemoradiation (long OS). However, the difference between
Fig. 4 a Spearman correlation analysis of imaging biomarkers with PFS and OS at days +15 and +29. b Kaplan–Meier log-rank survival plots at
day +29 for tCho/hCr, rCBF, FLAIR volume, and ce-T1 volume. c Spearman correlation analysis between tCho/hCr and rCBF, FLAIR or ce-T1 at
day +29
MRSI as biomarker of response in GBM
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metabolic activity of responders (long OS) and non-responders
(short OS) decreases toward the end of chemoradiation, which is
mirrored by similar behavior of rCBF. This suggests that AA
therapy might counter the effect of cytotoxic therapy late in the
treatment. Prolonged and high-dose AA therapy may lead to
excessive pruning of tumor blood vessels during the late stages of
the treatment,16 which may explain the late (post day +29)
decrease of rCBF in our data (Fig. 2). In addition, decreased
permeability of BBB as probed by Ktrans imaging18, 30 (shown in
Supplementary Fig. 3) may interfere with tumor delivery of drugs
such as temozolomide. Likely, there is a delay between early
synergistic and late antagonistic effects of AA therapy and these
complex dynamics may explain in part why therapeutic beneﬁt
has a limited duration.16 On the other hand, in non-responsive
patients the angiogenesis may not be VEGF-dependent,14, 16
hence the blockade of the VEGF pathway will not result in a
beneﬁt.
In the cohort of 21 patients treated by the combination of AA
and chemoradiation, the tCho/hCr ratio at day +29 was most
signiﬁcantly associated with OS, having the largest AUC and HR as
an individual biomarker. The second best imaging biomarker to
predict OS was rCBF. Several multiparametric imaging studies
showed that combining multiple parameters has superior
performance.30, 32, 33 We explored this possibility by combining
the best two imaging biomarkers tCho/hCr and rCBF. The
combined tCho/hCr + rCBF index had a larger AUC than individual
biomarkers, and achieved more signiﬁcance in Cox proportional
hazard models compared with other predictors of treatment
response such as MGMT methylation status.25 The higher AUC of
tCho/hCr + rCBF may be explained by the fact that it captures the
full effect of combined therapy, tCho/hCr being sensitive to effects
of chemoradiation while rCBF probes mostly the effects of AA
treatment. We found that MGMT status differed signiﬁcantly
(Mann–Whitney test, P = 0.04) between short OS and long OS
patients groups, which are stratiﬁed based on the cut-off value of
tCho/hCr. This association provides a potential mechanism for
tCho/hCr sensitivity to chemoradiation effects.
Our results support the possibility that metabolic and physio-
logic imaging biomarkers can be used to: (1) identify responsive
patients, and (2) overcome resistance and improve response to AA
therapy.34 By monitoring treatment with longitudinal metabolic
and physiologic imaging, the dosing regimens can be adjusted
during the course of treatment to balance the effects of AA and
cytotoxic therapy.
Despite its potential, MRSI is underutilized compared with other
MR modalities owing to several limitations. These include
suboptimal pulse sequences offered as clinical protocols by
vendors, lack of standardization, complex quantiﬁcation and
analysis, as well as difﬁcult integration of anatomical and
metabolic information.35 These limitations result in less reprodu-
cibility and more variability, which lead to less acceptance, fewer
studies with smaller number of patients, and less validation. We
addressed some of the limitations in our study by employing a
custom designed pulse sequence with improved localization,
atlas-based positioning of MRSI for improved reproducibility
across longitudinal imaging, and spectral ﬁtting based on prior
knowledge basis sets.
The small number of patients imposes some limitation on the
statistical analysis of our data. In a small cohort only biomarkers
that show a large effect size can be tested, multivariate analysis is
limited to few variables, and the sampling bias cannot be
excluded. However, recent studies36, 37 performed with more
subjects support the value of MRSI to monitor treatment response
in GBM patients. Taken together, our study and others advocate
for an earlier imaging investigation time point around the middle
of radiotherapy period in GBM. Currently, most clinical protocols
have follow-up scans that are farther away in time, after
radiotherapy.
In summary, our study may provide information that is relevant
to further understand the mechanisms of beneﬁt from AA therapy
in GBM, to potentially explain why some patients respond and
others fail, the limited duration for which therapeutic beneﬁt is
noticed, and the mechanism of action of these agents.38, 39
Metabolic proﬁles obtained by MRSI are complementary to other
imaging biomarkers, and our study supports the role of MRSI for
comprehensive GBM patient evaluation in future clinical care and
in clinical trials.
METHODS
Methods were performed in accordance with relevant guidelines and
regulations. Methods were approved by the Internal Review Board
committee of Massachusetts General Hospital and Dana-Farber Cancer
Institute, Boston, MA.
Patient eligibility and treatment planning
A cohort of 40 newly diagnosed GBM patients were enrolled in a phase Ib/
II clinical trial of cediranib performed concurrently at Massachusetts
General Hospital and Dana-Farber Cancer Institute, Boston, MA
(ClinicalTrials.gov identiﬁer NCT00662506). All patients participating in this
study signed an Internal Review Board approved informed consent form.
After 2–3 weeks from surgery, patients received 6 weeks of daily,
fractionated radiation with temozolomide. One month following the
completion of chemoradiation, temozolomide resumed at 150–200mg/m2
for 6 months. Cediranib was given 30mg/day orally, starting concomitantly
with chemoradiation and continuing without interruption until disease
progression or toxicity. Inclusion criteria for all patients were: age ≥18
years with pathology-proven GBM after biopsy or resection who were
eligible to receive standard postsurgical temozolomide and radiation,
evidence of residual contrast-enhancing tumor ≥1 cm on postsurgical MRI
in at least one dimension, a KPS≥ 60 and Mini-Mental Status Examination
score (MMSE) >15, adequate organ and bone marrow function, no
concomitant enzyme-inducing anti-epileptic drugs, and no prior anti-VEGF
therapy.
Magnetic resonance imaging
MR data were acquired with a 3.0 T magnetic resonance scanner (TIM Trio,
Siemens Healthcare, Erlangen, Germany). The system’s standard 32-
channel phased-array head coil was used for imaging. Patients had to be
on a stable dose of steroids for 5 days before MRI. The scan time points
were performed at days −5 and −1 (baselines) before treatment start, and
during treatment at days +1, +8, +15, +22, +29, +36, +43, +50, and
monthly thereafter.
MR imaging included anatomical pre-contrast and post-contrast 2D T1-
weighted gradient echo (repetition/echo times TR/TE = 600/12ms, 5 mm
slice thickness, 1 mm inter slice gap, 0.43mm in-plane resolution, 23 slices,
512 × 512 matrix), 2D T2-weighted spin echo FLAIR images (TR/TE =
10,000/70 ms, inversion time TI = 1500ms, 5 mm slice thickness, 1 mm inter
slice gap, 0.43 mm in-plane resolution, 23 slices, and 512 × 512 matrix), 3D
T2-SPACE (TR/TE = 3200/428ms, 1 mm isotropic, 256 × 256 × 176 matrix),
post-contrast 3D T1-MEMPRAGE (TI/TR/TE1/TE2/TE3/TE4 = 1200/2530/1.64/
3.5/5.36/7.22ms, 1 mm isotropic, 256 × 256 × 176 matrix). In addition,
functional imaging was obtained using dynamic contrast enhanced (DCE),
diffusion tensor imaging (DTI), and perfusion-weighted dynamic suscept-
ibility contrast (DSC), as following: DCE—TR = 7.3 ms, TE = 4.4 mm, 2.11-
mm slice thickness, 0-mm interslice gap, 20 slices, 1.8-mm in-plane
resolution 128 × 128 matrix, ﬁeld-of-view 230 × 230mm2, bolus of 0.1
mMol/kg injected after 52 s for DCE; DTI—spin-echo EPI, b-values = 0/700
s/mm2, 42 directions, TR/TE = 7980/84ms, 64 slices, 1.9 mm isotropic; DSC
—combined gradient-echo and spin-echo EPI sequence, TR/TE1/TE2 =
1480/32/93ms, 5 mm slice thickness, 1.5 mm slice gap, 12 slices, 1.2 mm
in-plane resolution, 160 × 160 matrix, 120 frames, a second bolus of 0.1
mMol/kg injected after 80 s for DSC. The contrast injected during DCE
served as pre-load dose for DSC scan to minimize effects of contrast agent
leakage. Post-contrast T1-weighted images were obtained after the
combined DSC + DCE dose of 0.2 mMol/kg of GD-DTPA.
Scan-to-scan reproducibility was improved by the Siemens automatic
positioning “AutoAlign” method.39 Pre-contrast and post-contrast T1-
weighted (ce-T1) and FLAIR images were quantitatively analyzed by an
independent neuroradiologist blinded to patient number, clinical data, and
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treatment status. The lesions were outlined and the volumetric measures
were carried out by summing the enhanced post-contrast voxels identiﬁed
within the lesions. rCBF maps were calculated in nordicICE with post-
processing leakage correction and normalization to normal appearing
white matter as previously described.31 Radiologic tumor response was
determined according to the updated RANO criteria for malignant
gliomas,19 taking into account clinical performance status, dose of steroids,
spatial dimensions, and temporal dynamics of contrast-enhancing lesions
and FLAIR signal abnormalities. Patients who demonstrated signs of
progression on imaging inside the radiation ﬁeld during the ﬁrst 12 weeks
after completion of chemoradiation were not considered to have tumor
progression and (if clinically feasible) were maintained on the same
treatment regimen and imaging surveillance. Clinical evaluations were
performed by treating the neuro-oncologists and included KPS and MMSE
scores.
Magnetic resonance spectroscopic imaging
2D single-slice MRSI was acquired using localization by adiabatic selective
refocusing (LASER) sequence40 with acquisition parameters of: TR/TE =
1500/45ms, FOV = 200 × 160mm2, acquisition matrix 20 × 16, 10 × 10mm2
in-plane voxel, slice thickness 15mm, NA = 1, elliptical phase encoding,
acquisition time TA = 5:02min:s. LASER selected a VOI, which typically had
an in-plane size between 80 × 80 and 100 × 100mm2. Shimming was
performed automatically using the method supplied by the manufacturer
up to water line width of 15 Hz over the VOI. Water suppression was
achieved using the water suppression enhanced through T-1 effects
scheme.41 AutoAlign method39 was used to reproduce consistently the
position of MRSI on all visits in a given patient.
MR spectra were ﬁtted with LCModel software42 and were further
processed and analyzed in MATLAB (Mathworks Inc., Natick, MA, USA).
Only voxels for which the goodness of ﬁt as measured by Cramer–Rao
lower bounds less than 20% were included in the quantitative analysis.
tCho, Cr, and N-acetyl-aspartate (NAA) yielded the largest number of
analyzable voxels. Lipid and lactate were overlapping at TE = 45ms and
could not be separated well. Voxel-wise metabolic ratios were calculated
for tCho/NAA, while for tCho/Cr the mean value of Cr in the normal
appearing white matter (hCr) was ﬁrst calculated and then used to
normalize tCho values in all voxels (further referred as tCho/hCr maps).
Mean values of tCho/NAA and tCho/hCr were calculated over the tumor
ROI determined on the contrast-enhanced T1-weighted images. Since in
some cases the tumor ROI on contrast T1-weighted images disappeared
for some of the scans after start of AA treatment, we used the baseline ROI
to calculate mean ROI metabolic ratios for all the visits. The region of
normal appearing white matter was deﬁned in the contralateral hemi-
sphere. This region included 10–20 MRSI voxels that were selected
contiguously in white matter, away from any abnormality and avoiding
gray matter and CSF.
Statistics
Based on the median survival threshold, two groups of histologically
conﬁrmed newly diagnosed GBM patients were identiﬁed and their clinical
parameters, MR imaging, and spectroscopy data were evaluated and
compared. To investigate the association between the analyzed MR data
and OS and PFS in GBM patients after treatment, Kaplan–Meier curves and
log-rank analysis were performed. ROC curve analysis was performed on
anatomical MRI and MRSI parameters to establish cut-off values to evaluate
the predictive capability of the MR modalities for OS time after 4-week
treatment. The AUC for FLAIR volume, ce-T1 volume, rCBF, and tCho/hCr
were obtained at 4-week post-treatment time point. Univariate and
multivariate Cox proportional hazards model were ﬁt to evaluate any
association between MR biomarkers and OS. GraphPad Prism 7 software
(GraphPad Software, Inc., La Jolla, CA) was used for statistical analysis.
Data availability
The data sets generated during and/or analyzed during the current study
are available from the corresponding author on reasonable request.
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